2BuchananJF, Brown CR. Designer drugs. A problem in clinical toxicology[J]. Medical Toxicology and Adverse Drug Experience 1988, 3 (1): 1-17.
3Wyler LS. International drug control policy[M]. Analyst in International Crime and Narcotics, 2009.
4Snyder SH, Faillace L, Hollister L. 2. 5-dimethoxy-4- methyl-amphetamine (STP): a new hallucinogenic drug[J]. Science, 1967, 158 (80l): 669-670.
5Henderson GL. Designer drugs: past history and future prospects[J].J Forensic Sci. 1988. 33 (2): 569-575.
6Cole MD Lea C. Oxley N. 4-Bromo-2,5-dimethoxyphen?ethylamine (2C-B): A review of the public domain liter?ature[J]. Science &Justice:Journal of the Forensic Science Society. 2002. 42 (4): 223-224.
7De Boer D. Bosman 1. A new trend in drugs-of-abuse: the 2C-series of phenethylamine designer drugs[J]. Pharmacy world & Science: 2004. 26 (2): 110-113.
8Uchiyama N. Kikura-Hanajiri R. Kawahara N. et al. A?nalysis of designer drugs detected in the products pur?chased in fiscal year 2006[J]. Yakugaku zasshi ,Journal of the Pharmaceutical Society ofJapan. 2008, 128 (0): 1499-1505.
9Malvey TC, Armsey Td. Tetrahydrogestrinone , The discovery of a designer steroid[]]. Current sports medicine reports, 2005, 4 (4): 227-230.
10HuffmanJW, Dai D, Martin BR, et al, Design. syn?thesis, and pharmacology of cannabimimetic indoles[J]. Biomed Chern, 1994, 4: 563-566.
